> ## Content Index > Fetch the complete content index at: https://barna.news/llms.txt > Use this file to discover other available public pages before exploring further. # New Drug Boosts Survival in Advanced Endometrial Cancer - URL: https://barna.news/new-drug-boosts-survival-in-advanced/ - Published: 2026-11-04T17:25:32.000Z - Updated: 2026-11-04T17:25:32.000Z - Description: A global trial led by Catalan hospitals shows a new antibody-drug conjugate significantly improves survival for patients with advanced endometrial cancer. - Author: Barna.News News Desk - Tags: health, Catalonia ## Major Advance in Endometrial Cancer Treatment An international clinical trial involving the Catalan Institute of Oncology (ICO) in L'Hospitalet and Girona has shown that a new drug, sacituzumab tirumotecan (sac-TMT), significantly improves survival in patients with advanced or recurrent endometrial cancer who have stopped responding to standard therapies. The phase 3 TroFuse-005/ENGOT-en23/GOG-3095 trial, presented at the European Society for Medical Oncology (ESMO) Congress 2026 and published in *The Lancet*, included 776 patients across nearly 30 countries. All had previously received platinum-based chemotherapy and immunotherapy, leaving them with limited treatment options. At a median follow-up of 14.0 months, patients receiving sac-TMT had a median progression-free survival of 7.2 months, compared to 3.9 months for those on standard chemotherapy. This represents a 41% reduction in the risk of disease progression or death. --- ## Improved Overall Survival and Tolerability Median overall survival was 19.0 months in the sac-TMT group, versus 12.1 months in the control group, a 32% reduction in the risk of death. The drug also achieved a confirmed objective response rate of 35.1%, more than double the 17.3% seen with standard treatment. Sac-TMT is an antibody-drug conjugate that targets TROP2, a protein overexpressed in over 90% of endometrial cancers. It delivers chemotherapy directly to cancer cells, reducing damage to healthy tissue. Dr Marta Gil, an oncologist at ICO L'Hospitalet, said: > “In recent years, we have incorporated immunotherapy, which has represented a significant advance. However, after chemotherapy and immunotherapy, we were left without effective tools. This study is the first to achieve a very significant improvement in patient survival.” Dr Beatriz Pardo, also from ICO L'Hospitalet, noted that the drug’s side effect profile differs from conventional chemotherapy, allowing for longer, more sustainable treatment. --- ## Regulatory Review Underway Based on these results, the U.S. Food and Drug Administration (FDA) has accepted for priority review a biologics license application for sac-TMT. A decision is expected by 15 June 2027\. The trial marks the first global phase 3 study to show statistically significant improvement in both progression-free and overall survival in this patient group. The findings offer new hope for a population with historically poor prognosis and limited options. --- *Sources:* [*LHDigital (L'Hospitalet)*](https://lhdigital.cat/noticies/un-nou-farmac-millora-la-supervivencia-en-el-cancer-dendometri-avancat/?ref=barna.news)*,* [*onclive.com*](https://www.onclive.com/view/sac-tmt-improves-pfs-and-os-is-under-fda-priority-review-in-previously-treated-endometrial-cancer?ref=barna.news)*,* [*SMC Spain*](https://sciencemediacentre.es/en/new-drug-shows-efficacy-against-advanced-endometrial-cancer-according-phase-3-trial?ref=barna.news)*,* [*merck.com*](https://www.merck.com/news/sacituzumab-tirumotecan-sac-tmt-reduced-the-risk-of-death-by-32-and-the-risk-of-disease-progression-or-death-by-41-compared-to-chemotherapy-in-certain-patients-with-advanced-or-recurrent-endometrial/?ref=barna.news)*.* --- ### Related on Barna.News - [Liver Cancer Vulnerability Identified by VHIO Study](https://barna.news/liver-cancer-vulnerability-identified/) - [Barcelona Pharmacists Identify 70 at Stroke Risk](https://barna.news/barcelona-pharmacists-identify-70-at/) - [Blood Test Helps Spot Hidden MS Activity](https://barna.news/blood-test-helps-spot-hidden-ms-activity/)